123 results
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
5 Jun 24
Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2023 for Autolus Therapeutics plc
4:35pm
be expected to influence the economic decisions of the users of the financial statements. Materiality provides a basis for determining the nature … misappropriation due to the significance of the cash balance as well as the nature of it. We considered the risk over cash disbursement to be higher, and we
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
50% 23% 8% 71% ICANS Grade 3 7% 7% 0% 22% 1. Ghorashian et al., Nature Medicine 2019 2. Roddie et al, ASH 2023 3. USPI 2023, Maude et al., NEJM 2018
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
, Autolus announced the publication of a paper in Nature Communications entitled: ‘Structure-Guided Engineering of Immunotherapies Targeting TRBC1
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
in any criminal proceeding or a penalty imposed by a regulatory authority for non-compliance with any requirement of a regulatory nature, (iii
10-K
pqshbv5
21 Mar 24
Annual report
4:55pm
10-K
EX-10.12
0gjem4bq55ysel
21 Mar 24
Annual report
4:55pm
8-K/A
EX-99.1
ab51bt7j 1hh
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.2
4zo t9q3d5
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
heqwgw5hpvd
14 Mar 24
Results of Operations and Financial Condition
12:32pm
D
7mc hikxsosk9zg9ky
23 Feb 24
Exempt offering of security
5:28pm
8-K
EX-99.1
234s3g6urwog655 3fd
13 Feb 24
Regulation FD Disclosure
4:06pm
424B5
0rkjto lzf
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-1.1
cxc op6eop293gr
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
niffartc 6h
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-10.1
q7h75z07fbud3y
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
0vhv7r 35u5s10e
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
EX-4.7
vhjw47fc
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
k035nelqycfyyu5xm al
7 Feb 24
Automatic shelf registration
10:00pm
8-K
EX-99.2
xoxbyyos7cr4stoa
11 Dec 23
Regulation FD Disclosure
8:31am